Abstract
The rationale for using transfer factor (TF) in lung cancer patients is that the possibility of improving their cell-mediated immunity to tumour associated antigens (TAA) may improve their survival. From Jan 1984 to Jan 1995, 99 non-small cell lung cancer (NSCLC) resected patients were monthly treated with TF, extracted from the lymphocytes of blood bank donors. In the same period, 257 NSCLC resected patients were considered as non-treated controls. The survival rates of the TF treated group appear significantly improved both for patients in stages 3a and 3b, and patients with histological subtype “large cell carcinoma” (P<0.02). Survival of TF treated patients is also significantly higher (P<0.02) for patients with lymphnode involvement (N2 disease). The results of this study suggest that the administration of TF to NSCLC resected patients may improve survival.
Similar content being viewed by others
Abbreviations
- CMI:
-
cell-mediated immunity
- NSCLC:
-
non-small cell lung cancer
- TAA:
-
tumour-associated antigens
- TF:
-
transfer factor
References
Levin AS, Byers VS, Fudenberg HH, Wybran J, Johnston JO & Hackett AJ. Osteogenic sarcoma: immunologic parameters before and during immunotherapy with tumour specific transfer factor. J Clin Inv 1975; 55: 487–97.
Pizza G, Viza D, Boucheix CI & Corrado F. In vitro production of a transfer factor specific for transitional cell carcinom of the bladder. Br J Canc 1976; 33(6): 606–12.
Pizza G, Viza D, Boucheix C & Corrado F. Effect of in vitro produced transfer factor on the immune response of cancer patients. Eur J Canc 1977; 13(9): 917–23.
Pizza G, Viza D, Boucheix CI & Corrado F: Studies with in vitro produced transfer factor In: Ascher MS, Gottlieb AA, Kirkpatrick CH, eds. Transfer factor: basic properties and clinical applications. New York: Academic Press, 1976: 173–85.
Humphrey EW, Smart CR & Winchester DP. National survey of the pattern of care for carcinoma of the lung. J Thor Surg 1990; 100: 837–43.
Naruke T, Goya T, Tsuchiya R & Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thor Surg 1988; 96:440–47.
Kirsh MM, Orringer MB, McAuliffe S, Schork MA, Katz B & Silva J. Transfer factor in the treatment of carcinoma of the lung. Ann Thorac 1984; 38: 140–45.
Fujisawa T, Yamaguchi Y, Kimura H, Arita M, Baba M & Shiba M. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984; 54: 663–669.
Busutti L, Blotta A, Mastrorilli M, Savorani G, Pizza G, & De Vinci C. Transfer factor adjuvant therapy in non-small-cell lung carcinoma. (NSCLC) after surgery and radiotherapy. J Exp Path 1987; 3(4): 565–68.
Whyte RI, Schork MA, Sloan H, Orringer MB & Kirsh MM. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac 1992; 53(3): 391–96.
Fujisawa T, Yamaguchi Y, Kimura K, Arita M, Shiba M & Baba M. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn J Surg 1984; 14(6): 452–58.
Fujisawa T, Yamaguchi Y & Kimura H. Transfer factor in restoration of cell mediated immunity in lung cancer patients. Jpn J Surg 1983; 13(4): 304–11.
Mountain CF: A new international staging system for lung cancer. Chest 1986; 89: 225–233.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pilotti, V., Mastrorilli, M., Pizza, G. et al. Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 9, 117–121 (1996). https://doi.org/10.1007/BF02628668
Issue Date:
DOI: https://doi.org/10.1007/BF02628668